{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "Dealbook", "document_type": "blogpost", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-thumbStandard.jpg"}], "abstract": "Shire is paying a 51 percent premium for NPS, and it is making a potentially risky deal ahead of an important regulatory ruling, Neil Unmack of Reuters Breakingviews writes.", "type_of_material": "Blog", "word_count": "476", "lead_paragraph": null, "pub_date": "2015-01-12T12:00:20Z", "_id": "54b3fee638f0d8623a3536bc", "byline": {"original": "By NEIL UNMACK", "person": [{"rank": 1, "role": "reported", "firstname": "Neil", "organization": "", "lastname": "UNMACK"}]}, "source": "The New York Times", "snippet": "Shire is paying a 51 percent premium for NPS, and it is making a potentially risky deal ahead of an important regulatory ruling, Neil Unmack of Reuters Breakingviews writes.", "web_url": "http://dealbook.nytimes.com/2015/01/12/shire-gambles-abbvie-break-up-fee-on-a-risky-deal/", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "value": "Ornskov, Flemming", "name": "persons"}, {"rank": "1", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "2", "value": "Shire PLC", "name": "organizations"}, {"rank": "1", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}], "headline": {"main": "Shire Gambles AbbVie Breakup Fee on a Risky Deal", "kicker": "DealBook"}}